NCT03507088View on ClinicalTrials.gov

Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

July 1, 2018

Study Completion Date

July 1, 2018

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Fluoroestradiol (18F)

A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.

Trial Locations (2)

200032

Cancer Hospital/ Institute, Fudan University, Shanghai

Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Zhimin Shao

OTHER

NCT03507088 - Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter